| Literature DB >> 25834816 |
Lifang Ding1, Zao Jiang2, Qiaoyun Chen3, Rong Qin4, Yue Fang3, Hao Li5.
Abstract
An increasing body of evidence has indicated that polymorphisms in the miRNA binding site of target gene can alter the ability of miRNAs to bind their target genes and modulate the risk of cancer. We aimed to investigate the association between a miR-520a binding site polymorphism rs141178472 in the PIK3CA 3'-UTR and the risk of colorectal cancer (CRC) in a Chinese Han population. The polymorphism rs141178472 was analyzed in a case-control study, including 386 CRC patients and 394 age- and sex-matched controls; the relationship between the polymorphism and the risk of colorectal cancer was examined. Individuals carrying the rs141178472 CC genotype or C allele had an increased risk of developing CRC (CC versus TT, OR (95% CI): 1.716 (1.084-2.716), P = 0.022; C versus T, OR (95% CI): 1.258 (1.021-1.551), P = 0.033). Furthermore, the expression of PIK3CA was detected in the peripheral blood mononucleated cell of CRC patients, suggesting that mRNA levels of PIK3CA might be associated with SNP rs141178472. These findings provide evidence that a miR-520a binding site polymorphism rs141178472 in the PIK3CA 3'-UTR may play a role in the etiology of CRC.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25834816 PMCID: PMC4365313 DOI: 10.1155/2015/373252
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
General characteristics of colorectal cancer cases and controls.
| Cases ( | Controls ( |
| |||
|---|---|---|---|---|---|
| Age (mean ± SD), years | 60.1 ± 12.3 | 60.7 ± 12.9 | 0.506 | ||
| Gender | |||||
| Male | 216 | 56.0% | 229 | 58.1% | 0.563 |
| Female | 170 | 44.0% | 165 | 41.9% | |
| Smoking | |||||
| Never | 262 | 67.9% | 276 | 70.1% | 0.536 |
| Ever | 124 | 32.1% | 118 | 29.9 | |
| Family history of cancer | |||||
| No | 332 | 86.0% | 360 | 91.4% | 0.023 |
| Yes | 54 | 14.0% | 34 | 8.6% | |
| Tumor site | |||||
| Colon | 212 | 54.9% | |||
| Rectum | 174 | 45.1% | |||
| Tumor stages | |||||
| I | 38 | 9.8% | |||
| II | 173 | 44.8% | |||
| III | 135 | 35.0% | |||
| IV | 40 | 10.4% | |||
The association between rs141178472 and CRC risk.
| SNP | Genotype | Cases | Controls | Odds ratio (95% CI) |
|
|---|---|---|---|---|---|
| rs141178472 | TT | 156 (40.4) | 180 (45.7) | ||
| CT | 172 (44.6) | 175 (44.4) | 1.134 (0.840–1.531) | 0.444 | |
| CC | 58 (15.0) | 39 (9.9) |
|
| |
| T | 484 (62.7) | 535 (67.9) |
| ||
| C | 288 (37.3) | 253 (32.1) |
|
Figure 1Effect of the PIK3CA 3′-UTR polymorphism rs141178472 on PIK3CA expression. (a) The sequence complementarity of hsa-miR-520a and PIK3CA 3′-UTR is shown here. (b) Luciferase activity of plasmids containing rs141178472 T or C allele in 293T cells. PIK3CA 3′-UTR luciferase reporter plasmids were cotransfected with chemically synthesized mature hsa-miR-520a or negative control (NC) in 293T cells. (c) The PIK3CA mRNA levels in PBMCs of CRC patients were detected by qRT-PCR assay. *Compared to TT genotype, P < 0.05.